Диссертация (1335925), страница 25
Текст из файла (страница 25)
– Vol. 461, № 7262. – P. 399–401.182. George, S. L. Clinical, Virologic, Histologic, and Biochemical Outcomes After SuccessfulHCV Therapy: a 5-Year Follow-up of 150 Patients / S. L. George, B Bacon, E Brunt [et al.] //Hepatology. – 2009. – № 49. – P. 729–738.183. Ghany, M. Predicting clinical outcomes usingbaseline and followup laboratory datafrom thehepatitis C long-termtreatment against cirrhosis trial / М. Ghany, Н. Kim, А.Stoddard // JournalHepatology.
– 2011. – Vol. 54. – P. 1527–1537.184. Ghany, M. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011practice guideline by the American Association for the Study of Liver Diseases / М. Ghany,D. Nelson, D. Strader [et al. ] // Journal Hepatology. – 2011. – Vol. 54, № 4. – P. 1433–1444.185. Giannini,E.Validityandclinicalutilityoftheaspartateaminotransferase-alanineaminotransferase ratio in assessing disease severity and prognosis inpatients with hepatitis Cvirus-related chronic liver disease / E. Giannini, D. Risso, F. Botta [et al.] //Arch Intern Med.
– 2003. –Vol. 163. – Р. 218–224.186. Gill, J. The effect of ABO blood group on the diagnosis of von Willebrand disease / J. Gil,J. Endres-Brooks, P.Bauer [et al.] // Blood. – 1987. – Vol. 69, № 6. – Р. 1691–1695.187. Gonzälez-Navajas, J. Immunomodulatory functions of type I interferons / J. GonzälezNavajas, J. Lee, M. David, E. Raz // Nat. Rev. Immunol. – 2012.
– № 12 (2). – P. 125–135.188. Goodman, Z. Fibrosis Progression in Chronic Hepatitis C: Morphometric Image Analysis inthe HALT-C Trial / D. Goodman Zachary, A. Stoddard, H. Bonkovsky [et al.] // Hepatology. – 2009. –Vol. 50, № 6. – Р. 1738–1749.131189. Grebely, J. Potential role for lnterleukin-28B genotype in treatment decision-making inrecent hepatitis С virus infection / J. Grebely // Journal Hepatology.
– 2010. – Vol. 52. – P. 1216–1224.190. Guan, Y. Role of antiviral therapy in the management of hepatocellular carcinoma /Y. Guan, Q. He // Anticancer. Drugs. – 2013. – V. 24, № 4. – P. 337–343.191. Hadziyannis, S. Peginterferon-alfa2a and ribavirin combination therapy in chronic hepatitisС: а randomized study of treatment duration and ribavirin dose / S. Hadziyannis, H. Sette, T. Morgan[et al.] // Annаls of Internal Medicine. – 2004. – Vol.
140, № 5. – P. 346–355.192. Hajarizadeh, B. Epidemiology and natural history of HCV infection / B. Hajarizadeh,J. Grebely, G. Dore // Nat. Rev. Gastroenterol. Hepatol. – 2013. – № 9. – P. 553–562.193. Hanafinah K, Groeger J, Flaxman A, Wiersma S. Global epidemiology of hepatitis C virusinfection: new estimates of age-specific antibody to HCV seroprevalence / K. Hanafinah, J. Groeger,A. Flaxman [et al.] // Journal Hepatology. – 2013. – Vol.
57, № 4. – Р. 1333–1342.194. He, J. Influence of interleukin-28B polymorphism on progression to hepatitis virus-inducedhepatocellular carcinoma / J. He, G. Yu, Z. Li, H. Liang // Tumor. Biol. – 2014. – № 35. – P. 57–63.195. Hedskog, C. Evolution of the HCV viral population from a patient with S282T detected atrelapse after sofosbuvir monotherapy / C.
Hedskog, H. Dvory-Sobol, V. Gontcharova [et al.] // J.Viral. Hepat. – 2015.196. Hewison, M. An update on vitamin D and human immunity / M. Hewison // Clin.Endocrinol. – 2012. – Vol. 76, № 3. – P. 315–325.197. Hezode, C. Triple therapyin treatment-experienced patients with HCVcirrhosisin amulticentre cohort of the FrenchEarly Access Programme (ANRS CO20-CUPIC) – NCT01514890 /C. Hezode, H. Fontaine, C.
Dorival [et al.] // J. Hepatol. – 2013. – № 59. – P. 434–441.198. Hézode, C. Effectiveness of Telaprevir or Boceprevir in Treatment-Experienced PatientsWith HCV Genotype 1 Infection and Cirrhosis/ С. Hézode, Helene Fontaine, Celine Dorival, FabienZoulim, Dominique Larrey [et al.] // Gastroenterology. – 2014. – V. 147, № 1.
– P. 132–142.199. Holmes, J. A. Interferon-free combination therapies for the treatment of hepatitis C: currentinsights / J. A. Holmes, A. J. Thompson // Hepat. Med. – 2015. – № 7. – P. 51–70.200. Hsu, С. Systematic Review: Impact of Interferon-based Therapy on HCV relatedHepatocellular Carcinoma. / C. Hsu, Y. Chao, H. Lin [et al.].
– URL: www.nature.com/shientificreports/5:09954/ [doi:10.1038/srep09954.w].201. Isaacs, A. Virus interference I. The interferon / A. Isaacs, J. Lindenman // Proc. R. Soc.Lond. B. Biol. Shi. – 1957. –Vol. 147. – P. 258–267.132202. Jacobson, L. М. WIN-R Study Group. Peginterferon alfa-2b and weight-based or flat-doseribavirin in chronic hepatitis С patients: a randomized trial / L. М. Jacobson, R.
S. Brown Jr., В. Freilich[et al.] // Hepatology. – 2007. – No. 46. – P. 971–981.203. Jacobson, I. M. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatmentnaive patients with chronic hepatitis С virus genotype 1 infection (QUEST-1): a phase 3, randomised,double-blind, placebo-controlled trial / I. M. Jacobson, G. J. Dore, G. R. Foster [et al.] // Lancet. –2014.
– No. 384 (9941). – P. 403–413.204. Jacobson, I. M. Telaprevir for previously untreated chronic hepatitis С virus infection /I. M. Jacobson, J. G. McHutchison, G. Dusheiko, et al. // N. Engl. J. Med. – 2011. – No. 364. –P. 2405–2416.205. Jamma, S. Current Concepts of HBV/HCV coinfection: coexistence, but not necessarily inharmony / S. Jamma, G. Hussain, D. T. Lau // Curr. Hepat.
Rep. – 2010. – Vol. 9. – Р. 260–269.206. Joshita, S. Association of IL28B gene polymorphism with development of hepatocellularcarcinoma in Japanese patients with chronic hepatitis C virus infection / S. Joshita, T. Umemura,Y. Katsuyama [et al.] // Hum. Immunol. – 2012. – No. 73. – P. 298–300.207. Kelly, C. Interferon lambdas: the next cytokine storm / C. Kelly, P. Kienerman, E. Barnes //Gut. – 2011. – Vol. 60 (9).
– P. 1284–1293.208. Khalil, U. Prohepcidin Level Is Decreased In Patients with Chronic Viral C Hepatitis, andHas No Correlation with Disease Progression [Electronic resonrce] / Usama Khalil, Monkez Motae,Abdullah Abelaziz, Alsayed Ahmed Alnahal, Mahmoud Ashour // J. Am. Sci. – 2012. –№ 8 (9). –P. 333.
– URL: http://www.jofamericanscience.org.209. Kitson, М. Interleukin-28B rs12979860 C allele: Protective against advanced fibrosis inchronic hepatitis C genotype 1 infection / М. Kitson, J. George, R. Leung [et al.] // Journal ofGastroenterology and Hepatology/ – 2014. – No. 29. – P. 1458–1462.210. Kocabayoglu, P. β-PDGF receptor expressed by hepatic stellate cells regulates fibrosis inmurine liver injury, but not carcinogenesis / P.
Kocabayoglu, A. Lade, Y. A. Lee, A. Dragomir [et al.]// J. of Hepatology. – 2015. – № 63. – P. 141–147.211. Konerman, M. A. Systematic review: identifying patients with chronic hepatitis Cin need ofearly treatment and intensive monitoring –predictors and predictive models of disease progression /M. A.
Konerman, S. Yapali, A. S. Lok // Aliment. Pharmacol. Ther. – 2014. – No. 40. – P. 863–879.212. Kowdley, K. V. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatmentnaive patients with hepatitis С genotype-1 infection (ATOMIC): an open-label, randomised,multicentre phase 2 trial / K. V. Kowdley, E. Lawitz, I. Crespo [et al.] // Lancet. – 2013. – Vol. 381,No. 9883. – P. 2100–2107.213. Krishnan, P. Long-term follow-up of treatment-emergent resistance-associated variants in133NS3, NS5A and NS5B with paritaprevir/r, ombitasvirand dasabuvir-based regimens / P.
Krishnan,R. Tripathi, G. Schnell [et al.] // J. Hepatol. – 2015. – No. 62. – S220–S220.214. Krishnan, P. Resistance analysis of baseline and treatment-emergent variants in hepatitis Cvirus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir /P. Krishnan, R. Tripathi, G. Schnell [et al.] // Antimicrob. Agents. Chemother.
– 2015. – № 59. –P. 5445–5454.215. Lagging,M.DITTO-HCVStudyGroup.IP-10predictsviralresponseandtherapeuticoutcome in difficult-to-treat patients with HCV genotype 1 infection. / M. Lagging, A. I.Romero, J. Westin [et al.] // Hepatology. – 2006. – № 44 (6). – P. 1617–1625.216. Lai, C. Telbivudine versus lamivudine in patients with chronic hepatitis B / C. Lai, E.
Gane,Y. Liaw [et al.] // N. Engl. J. Med. – 2007. – V. 35. – P. 2576–2588.217. Lange, C. M. Vitamin D receptor and Jak-STAT signaling crosstalk results incalcitriolmediated increase of hepatocellular response to IFN-alpha / C. M Lange, J. Gouttenoire, F. H.Duong [et al.] // J. Immunol. (Baltimore, Md., 1950). – 2014. – № 192 (12). – P.
6037–6044.218. Lavanchy, D. Evolving epidemiology of hepatitis C virus / D. Lavanchy // Clin. Micrbiol.Infect. – 2011. – Vol. 17, № 2. – Р. 107–115.219. Lawitz, E. Sofosbuvir for previously untreated chronic hepatitis С infection / E. Lawitz,A. Mangia, D. Wyles [et al.] // N. Engl. J. Med. – 2013. – Vol. 368, N 20. – P. 1878–1887.220. Lawitz, E.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
